Azitra, Inc. (AZTR) Research

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

Market snapshot

Symbol
AZTR
Price
$0.17
Day change
-15.42%
Market cap
$1.8M
P/E ratio
-0.23x
52-week range
0.1-1.83333
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Why Are Shares Of Azitra Rising?

    Azitra's spike is being fueled by a securities purchase agreement with healthcare-focused institutional investors for gross proceeds of up to $31.4 million, with Series B and C warrants exercisable at $0.123 per share and Series A convertible preferred priced at $1,000 per share.

  • Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending

    Azitra shares jumped over 44% in after-hours trading following a $31.4 million financing deal to advance its filaggrin protein and peptide platform.

Peer companies

  • Enveric Biosciences, Inc. (ENVB)
  • Indaptus Therapeutics, Inc. (INDP)
  • Jasper Therapeutics, Inc. (JSPR)
  • Lipella Pharmaceuticals Inc. (LIPO)
  • Onconetix, Inc. (ONCO)
  • Revelation Biosciences, Inc. (REVB)
  • Scinai Immunotherapeutics Ltd. (SCNI)
  • Salarius Pharmaceuticals, Inc. (SLRX)

Recent insider activity

  • Salva Francisco D. — C-Conversion (4064050 shares) on 2026-06-16
  • Salva Francisco D. — C-Conversion (500 shares) on 2026-06-16
  • Staskey Norm — A-Award (35524 shares) on 2026-04-20
  • Salva Francisco D. — A-Award (220879 shares) on 2026-04-20
  • Whitfill Travis — A-Award (64300 shares) on 2026-04-20

Open Azitra, Inc. (AZTR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.